IN2014MN02539A - - Google Patents

Info

Publication number
IN2014MN02539A
IN2014MN02539A IN2539MUN2014A IN2014MN02539A IN 2014MN02539 A IN2014MN02539 A IN 2014MN02539A IN 2539MUN2014 A IN2539MUN2014 A IN 2539MUN2014A IN 2014MN02539 A IN2014MN02539 A IN 2014MN02539A
Authority
IN
India
Prior art keywords
features
vivo
favorable
analogues
compounds
Prior art date
Application number
Other languages
English (en)
Inventor
J L Kiappes
Peter Laing
Raymond Dwek
Nicole Zitzmann
Stephanie Pollock
Original Assignee
Unither Virology Llc
Univ Oxford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unither Virology Llc, Univ Oxford filed Critical Unither Virology Llc
Publication of IN2014MN02539A publication Critical patent/IN2014MN02539A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06Aminosugars
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
IN2539MUN2014 2012-06-06 2013-06-05 IN2014MN02539A (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656265P 2012-06-06 2012-06-06
PCT/US2013/044285 WO2013184780A1 (en) 2012-06-06 2013-06-05 Novel iminosugars and their applications

Publications (1)

Publication Number Publication Date
IN2014MN02539A true IN2014MN02539A (hu) 2015-07-24

Family

ID=49712581

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2539MUN2014 IN2014MN02539A (hu) 2012-06-06 2013-06-05

Country Status (8)

Country Link
US (1) US8921568B2 (hu)
EP (1) EP2858642A4 (hu)
JP (1) JP2015518896A (hu)
KR (1) KR20150035767A (hu)
CN (1) CN104703597A (hu)
CA (1) CA2875975A1 (hu)
IN (1) IN2014MN02539A (hu)
WO (1) WO2013184780A1 (hu)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113425720A (zh) * 2020-04-03 2021-09-24 深圳前海诺贝尔奖科学家技术转移转化有限公司 亚胺糖化合物在制备抗SARS-CoV-2病毒的药物中的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6011902B2 (ja) * 1979-12-27 1985-03-28 日本新薬株式会社 モラノリンの誘導体
DE3007078A1 (de) * 1980-02-26 1981-09-10 Bayer Ag, 5090 Leverkusen Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung
AU732552B2 (en) * 1996-07-15 2001-04-26 Genzyme Corporation Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
US6465487B1 (en) 1997-12-11 2002-10-15 Synergy Pharmaceuticals, Inc. Inhibition of membrane-associated viral replication
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
US6809083B1 (en) 1998-02-12 2004-10-26 Richard A. Mueller Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections
US6545021B1 (en) 1999-02-12 2003-04-08 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
WO2001010429A2 (en) * 1999-08-10 2001-02-15 The Chancellor, Masters, And Scholars Of The University Of Oxford Long chain n-alkyl compounds and oxa-derivatives thereof and use as antiviral compositions
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
CA2399802C (en) 2000-02-11 2009-12-08 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US20050119310A1 (en) * 2000-02-14 2005-06-02 Mueller Richard A. Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
EP1556036A2 (en) 2002-09-23 2005-07-27 The Chancellor, Masters And Scholars Of The University Of Oxford Use of iminosugar derivatives to inhibit ion channel activity
US7514461B2 (en) 2003-09-19 2009-04-07 Edison Pharmaceuticals, Inc. Chroman derivatives
WO2006073456A2 (en) * 2004-05-04 2006-07-13 Academia Sinica Anti-coronavirus compounds
KR100611931B1 (ko) 2004-09-02 2006-08-11 강경태 광학활성 알콕시알콜 화합물, 이로부터 유도되는 광학활성1,3-페닐렌-비스[4-(4-알콕시)페닐이미노메틸]벤조에이트화합물 및 이들의 제조방법
BRPI0609614A2 (pt) 2005-04-04 2010-04-20 Univ Pontificia Catolica Chile uso de ezetimiba na prevenção e tratamento de litìases de colesterol na árvore biliar
EP2023927B1 (en) 2006-05-24 2015-02-25 United Therapeutics Corporation Deoxynojirimycin and d-arabinitol analogs and methods of using
JP2009545621A (ja) 2006-08-02 2009-12-24 ユナイテッド セラピューティクス コーポレーション ウィルス感染症のリポソーム処置
KR20100127842A (ko) 2008-03-26 2010-12-06 유니버시티 오브 옥스퍼드 소포체 표적화 리포좀
WO2010027996A1 (en) * 2008-09-02 2010-03-11 Institute For Hepatitis And Virus Research Novel imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
KR20120042716A (ko) 2009-02-23 2012-05-03 유나이티드 세러퓨틱스 코오포레이션 이미노슈가 및 바이러스성 질환을 치료하는 방법
ES2562635T3 (es) 2009-02-24 2016-03-07 United Therapeutics Corporation Iminoazúcares y métodos de tratamiento de infecciones producidas por arenavirus
EP2410989A2 (en) 2009-03-27 2012-02-01 The Chancellor, Masters and Scholars of the University of Oxford Cholesterol level lowering liposomes
CA2765086C (en) 2009-06-12 2015-12-15 United Therapeutics Corporation Iminosugars and methods of treating bunyaviral and togaviral diseases
US20110065754A1 (en) 2009-09-04 2011-03-17 United Therapeutics Corporation Iminosugars and methods of treating filoviral diseases
CN102625801B (zh) 2009-09-04 2015-09-09 联合治疗公司 治疗痘病毒感染的方法
JP5653438B2 (ja) 2009-09-04 2015-01-14 ユナイテッド セラピューティクス コーポレイション オルトミクソウイルス感染の治療方法
EP2509598A1 (en) 2009-12-07 2012-10-17 The Chancellor, Masters And Scholars Of The University Of Oxford N-substituted deoxynojirimycin compounds for use in inhibiting osteoclastogenesis and/or osteoclast activation

Also Published As

Publication number Publication date
CA2875975A1 (en) 2013-12-12
EP2858642A4 (en) 2015-12-02
KR20150035767A (ko) 2015-04-07
EP2858642A1 (en) 2015-04-15
US20130331578A1 (en) 2013-12-12
CN104703597A (zh) 2015-06-10
JP2015518896A (ja) 2015-07-06
WO2013184780A1 (en) 2013-12-12
US8921568B2 (en) 2014-12-30

Similar Documents

Publication Publication Date Title
NZ732777A (en) Ionizable cationic lipid for rna delivery
EA201591662A1 (ru) Липиды и липидные композиции для доставки активных агентов
CR20130617A (es) Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias
EA201201343A1 (ru) Производные 4-аминопиримидина и их действующее вещество как антагонисты аденозинового рецептора а
MX2022006512A (es) Lipidos cationicos de trialquilo y metodos de uso de los mismos.
EA201590693A1 (ru) Ингибиторы gdf-8
PH12015501385A1 (en) Autotaxin inhibitors
MX2015005953A (es) Triazolopirazinas.
MX341332B (es) Lipidos biodegradables para la administracion de agentes activos.
EA201492112A1 (ru) ЗАМЕЩЕННЫЕ 3,4-ДИГИДРО-2H-ПИРИДО[1,2-a]ПИРАЗИН-1,6-ДИОНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ ДЛЯ ЛЕЧЕНИЯ (В ТОМ ЧИСЛЕ) БОЛЕЗНИ АЛЬЦГЕЙМЕРА
TW200736234A (en) Chemical compounds
IN2014DN00277A (hu)
FR2977486B1 (fr) Compositions cosmetiques sous la forme d'emulsions eau-dans-huile comprenant un derive d'acide jasmonique
MX357759B (es) Formulaciones y formas de dosificacion de fosfolipidos oxidados.
ECSP099382A (es) Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i
IN2014DN01619A (hu)
EP3133073A3 (en) Inhibitors of iap
RU2016109986A (ru) Композиция для подавления раковых заболеваний крови или метастазирования рака, содержащая в качестве активного ингредиента моноацетилдиглицеридное соединение
EP4302825A3 (en) Pharmaceutical compositions for treatment of inappetence
EP4321218A3 (en) Cancer stem cell targeted cancer vaccines
IN2014MN02539A (hu)
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same
EP2815742A4 (en) IMPROVED ADMINISTRATIVE FORM WITH EXTRACT FROM THE RINDER OF LIRIODENDRON TULIPIFERA AS AN ACTIVE SUBSTANCE
WO2011136585A3 (ko) 글리세올린을 유효성분으로 포함하는 골질환 치료용 조성물
WO2012022796A3 (de) Neue kombinationen